|
We are a biopharmaceutical company focused on the development of Utuxin™, a novel monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. Utuxin™ (ublituximab) is a monoclonal antibody targeting the CD20 antigen on B-cell lymphocytes, bioengineered for enhanced biological activity. In addition to Utuxin™, we may pursue complementary technology and product acquisitions, in-licensing and investments.
We are located in New York City and are traded on the OTC Bulletin Board® under the ticker symbol "TGTX".
| Copyright © Manhattan Pharmaceuticals, Inc. All Rights Reserved. Privacy Policy. |